Academic Medical Center University of Amsterdam

Otsuka Pharmaceutical Co., Ltd. (Otsuka) hereby announces that Otsuka has obtained a favorable decision in a patent infringement action against Daicel Corporation (hereinafter "Daicel") and Advanced Medical Care Inc. (hereinafter "AMC"). As announced in the news release dated February 10, 2022, entitled 'Favorable Judgment on Lawsuit on Patent Right Held in Relation to Otsuka Pharmaceutical Foods Containing Equol', Otsuka obtained a favorable judgment from the Intellectual Property High Court on February 9, 2022 in a patent infringement lawsuit against Daicel and AMC. In response to this judgment, Daicel and AMC filed a final appeal and a petition for acceptance of final appeal with the Supreme Court, but these have both been dismissed by the Supreme Court. With respect to Otsuka's patent right for Equol-containing foods (Patent Registration No. 6275313; Title of Invention: Equol-containing extract and method for producing the same, equol extraction method, and food containing equol; hereinafter the "Patent Right"), Otsuka filed a patent infringement action arguing that Daicel's act of manufacturing and selling "Flavocell EQ-5", and AMC's act of manufacturing and selling "Equol + Lactobionic Acid" using "Flavocell EQ-5" as a raw material infringed their patent. In this case, although the Tokyo District Court, the court of first instance, rendered a judgment dismissing Otsuka's claims on September 17, 2020, the Intellectual Property High Court, the court of second instance, overturned the judgment of the first instance and ruled in favor of Otsuka(*1) on February 9, 2022. The Supreme Court, the court of final appellate instance, dismissed the final appeal and refused to hear the case in its decisions dated November 11, 2022, and the decision of the Intellectual Property High Court, which found that a patent infringement had occurred and granted injunctions against the infringing parties, has thereby become final and binding (*2). Thus, Daicel is prohibited from manufacturing and selling "Flavocell EQ-5", and AMC is prohibited from manufacturing and selling "Equol + Lactobionic Acid" using "Flavocell EQ-5" as a raw material. Otsuka has filed multiple patent infringement actions seeking damages on the ground of infringement of the Patent Right by "Flavocell EQ-5" and supplement products using Flavocell EQ-5, which are now pending before the Tokyo District Court. Otsuka will continue to vigorously defend and protect its inventions in relevant fields of technology, and provide safeand high-quality products and information to support people's health based on scientific evidence. *1 Court Intellectual Property High Court Case number 2020 (Ne) #10059 Case name Appeal Case Seeking Injunction against Infringement of Patent Right Appellant (First Instance Plaintiff) Otsuka Pharmaceutical Co., Ltd. Appellee (First Instance Defendant) Daicel Corporation Appellee (First Instance Defendant) Advanced Medical Care Inc. *2 Court The Supreme Court Case number 2022 (O) #913 Case name Final Appeal Case Seeking Injunction against Infringement of Patent Right Final Appellant (Second Instance Appellee) Daicel Corporation Final Appellee (Second Instance Appellant) Otsuka Pharmaceutical Co., Ltd. Court The Supreme Court Case number 2022 (Ju) #1150 Case name Petition for Acceptance of Final Appeal Seeking Injunction against Infringement of Patent Right Petitioner (Second Instance Appellee) Daicel Corporation Respondent (Second Instance Appellant) Otsuka Pharmaceutical Co., Ltd. Court The Supreme Court Case number 2022 (Ju) #1151 Case name Petition for Acceptance of Final Appeal Seeking Injunction against Infringement of Patent Right Petitioner (Second Instance Appellee) Advanced Medical Care Inc. Respondent (Second Instance Appellant) Otsuka Pharmaceutical Co., Ltd.

The collaboration allows clinicians to offer RPM virtually to extend patient care outside the hospital to the home environment. They aim to combine GE Healthcare’s acute patient monitoring capabilities in the hospital with AMC’s expertise in RPM. According to a news release, GE Healthcare and AMC plan to leverage an FDA-cleared platform with analytics. They expect it to extend the continuum of non-acute care for patients after hospital discharge. “Pairing AMC Health’s remote patient monitoring suite with GE Healthcare’s clinical monitoring offering will extend care beyond the clinical setting and enable more patients to continue to receive quality care from the comfort of their homes, delivering healthcare without limits,” said Ashutosh Banerjee, GM, diagnostic cardiology and remote patient monitoring, GE Healthcare. “AMC Health was selected as our partner due to their established and proven success engaging with patients to measure numerous biometrics in the home to extend the continuum of care.” The AMC Health platform AMC Health’s RPM platform and data analytics offer hospitals, payers and providers a way to implement strategies for care coordination. Its holistic solution allows a clinical team to focus on the whole patient and their health conditions. Patients receive an easy-to-use, convenient monitoring platform with near-real-time data provided to clinicians to support treatment decisions. Chronic conditions monitored by the platform include diabetes, cardiovascular disease, and hypertension. The care team receives episodic data to create a complete picture of the patient’s condition. The companies intend for their collaboration to influence healthy behaviors. They also expect that, with clinician guidance, it can promote self-management for chronic conditions. They say their collaboration addresses a market need for a scalable RPM solution with analytics and risk stratification. The companies believe coupling AMC’s solution suite with GE’s large U.S. install base could expand the offerings around the country. “We are excited about this collaboration with GE Healthcare,” said Nesim Bildirici, CEO of AMC Health. “AMC Health is proud to align with a global leader in healthcare innovation and add our suite of RPM and Virtual Care Solutions to their extensive portfolio of global health system and hospital monitoring solutions.” GE Healthcare said RPM is complementary to its existing hospital-based virtual care environments. The two companies hope to integrate hospital and home data into the Edison Health database so hospitals can monitor patients post-discharge.